Literature DB >> 58073

Inhibition of infectious Rous sarcoma virus production by rifamycin derivative.

C Szabo, M J Bissell, M Calvin.   

Abstract

A new rifamycin derivative, rifazone-82 (R-82), an inhibitor of viral RNA-dependent DNA polymerase, is selectively toxic to transformed chicken cells in culture. R-82 has now been shown to possess antiviral activity as well. The relatively nontoxic properties of R-82 to nontransformed cells have permitted the execution of experiments examining the effect of a rifamycin derivative on virus reproduction. Addition of low concentrations of R-82 (15 mug/ml) to cultures soon after Rous sarcoma virus infection prevents the spread of infection thoroughout the culture. This inhibition is not dependent on concomitant cellular transformation as identical results were obtained with cells infected with a transformation-defective Rous sarcoma virus. Addition of R-82 to cultures in which all the cells are infected does not substantially affect the yield of physical particles as measured by RNA-dependent DNA polymerase activity and by (3H) uridine incorporation into viral RNA. However, the infectivity of the progeny virus, as measured by focus-forming ability, is decrreased 95 to 99% by R-82 treatment.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 58073      PMCID: PMC515569     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  Inhibition of influenza virus multiplication with a glucose antimetabolite (2-deoxy-D-glucose).

Authors:  E D KILBOURNE
Journal:  Nature       Date:  1959-01-24       Impact factor: 49.962

2.  Reverse transcriptase, RNA tumour virus transformation and derivatives of rifamycin SV.

Authors:  R C Ting; S S Yang; R C Gallo
Journal:  Nat New Biol       Date:  1972-04-12

3.  The inhibition of bacterial RNA synthesis by the rifamycin antibiotics.

Authors:  J M Wilhelm; N L Oleinick; J W Corcoran
Journal:  Biochim Biophys Acta       Date:  1968-08-23

4.  Noninfectious RSV deficient in DNA polymerase.

Authors:  H Hanafusa; T Hanafusa
Journal:  Virology       Date:  1971-01       Impact factor: 3.616

5.  Rifampicin: a specific inhibitor of vaccinia virus assembly.

Authors:  B Moss; E N Rosenblum; E Katz; P M Grimley
Journal:  Nature       Date:  1969-12-27       Impact factor: 49.962

6.  Effects of local cell concentrations upon the growth of chick embryo cells in tissue culture.

Authors:  A Rein; H Rubin
Journal:  Exp Cell Res       Date:  1968-03       Impact factor: 3.905

7.  Rifampicin inhibits the growth of some mammalian viruses.

Authors:  J H Subak-Sharpe; M C Timbury; J F Williams
Journal:  Nature       Date:  1969-04-26       Impact factor: 49.962

8.  Rifampicin and poxvirus replication.

Authors:  Z Ben-Ishai; E Heller; N Goldblum; Y Becker
Journal:  Nature       Date:  1969-10-04       Impact factor: 49.962

Review 9.  Actions of the rifamycins.

Authors:  W Wehrli; M Staehelin
Journal:  Bacteriol Rev       Date:  1971-09

10.  Biological and physical modifications of a murine oncornavirus by 2-deoxy-D-glucose.

Authors:  E V Prochownik; S Panem; W H Kirsten
Journal:  J Virol       Date:  1975-06       Impact factor: 5.103

View more
  3 in total

1.  Antiviral action of a rifamycin derivative: formation Rous sarcoma virus particles deficient in 60 to 70S RNA.

Authors:  C Szabo; M J Bissell
Journal:  J Virol       Date:  1978-03       Impact factor: 5.103

2.  Primary avian tendon cells in culture. An improved system for understanding malignant transformation.

Authors:  R I Schwarz; D A Farson; W J Soo; M J Bissell
Journal:  J Cell Biol       Date:  1978-12       Impact factor: 10.539

3.  Rifapentine is an entry and replication inhibitor against yellow fever virus both in vitro and in vivo.

Authors:  Xijing Qian; Bingan Wu; Hailin Tang; Zhenghan Luo; Zhenghao Xu; Songying Ouyang; Xiangliang Li; Jianfeng Xie; Zhigang Yi; Qibin Leng; Yan Liu; Zhongtian Qi; Ping Zhao
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 7.163

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.